Non-Alcoholic Steatohepatitis Treatment Market

Non-Alcoholic Steatohepatitis Treatment Market Latest Trends

The Non-Alcoholic Steatohepatitis Treatment Market is increasingly defined by the move from single-pathway liver therapy toward broader cardiometabolic management. Resmetirom established thyroid hormone receptor beta modulation as a validated therapeutic approach, while semaglutide expanded the field into incretin-based treatment. This creates a market in which liver-specific and systemic metabolic mechanisms can coexist instead of competing solely through one pharmacological pathway. Physicians can therefore consider fibrosis status, obesity, diabetes, cardiovascular risk, treatment route, tolerability, and metabolic phenotype when determining therapy.

Combination treatment is becoming a major development theme. Drug developers are testing strategies that pair liver-directed agents with metabolic compounds, RNA-based therapies, or mechanisms addressing lipid synthesis. Madrigal has positioned resmetirom as the foundation of several investigational combinations, including programs involving an oral GLP-1 receptor agonist and genetic targets linked to MASH. By June 2026, 49,000 patients were reported to be receiving Rezdiffra, illustrating the rapid transition from clinical-trial use to routine prescribing.

Non-invasive diagnosis is another defining trend. The historic dependence on liver biopsy has created practical barriers because biopsy is invasive, resource intensive, and difficult to scale across large metabolic populations. Treatment pathways increasingly incorporate vibration-controlled transient elastography, blood-based fibrosis scores, magnetic-resonance methods, and specialist algorithms to identify patients at risk of advanced fibrosis.

Pipeline differentiation is also shifting toward clinically meaningful multifunctionality. Candidates are increasingly expected to demonstrate effects on steatohepatitis, fibrosis, metabolic markers, body weight, or several of these outcomes together. The competitive focus is therefore moving from simple liver-fat reduction toward durable disease modification, easier administration, reduced monitoring burden, and compatibility with combination therapy.

Non-Alcoholic Steatohepatitis Treatment Market Dynamics

The Non-Alcoholic Steatohepatitis Treatment Market is shaped by expanding metabolic disease prevalence, increasing recognition of progressive liver fibrosis, new regulatory pathways, and greater use of specialist diagnostic tools. MASH frequently develops alongside obesity, type 2 diabetes, dyslipidemia, and other cardiometabolic disorders, giving treatment manufacturers access to overlapping patient populations already engaged with healthcare systems. The introduction of disease-specific pharmacotherapy has also changed how physicians view early fibrosis detection. Instead of identifying progressive disease without an approved therapeutic option, clinicians can increasingly connect diagnosis with active treatment. The central commercial and clinical dynamic is therefore shifting toward finding patients before cirrhosis develops. This shift favors companies with strong evidence in noncirrhotic fibrotic disease, convenient dosing, specialist education programs, payer-support capabilities, and clear non-invasive treatment algorithms. The first pivotal resmetirom approval was supported by a trial involving 888 patients, demonstrating the scale of evidence regulators required for initial market entry.

Drivers of Market Growth

Rising prevalence of metabolic disorders is expanding the treatable MASH population.

Obesity, insulin resistance, type 2 diabetes, dyslipidemia, and sedentary lifestyles create the biological conditions that drive hepatic fat accumulation and inflammatory liver injury. MASH is therefore increasingly managed as part of a systemic metabolic disease rather than an isolated hepatology condition. This expands referral opportunities from diabetes clinics, obesity programs, cardiovascular practices, primary-care networks, and gastroenterology services.

The clinical importance of this overlap is substantial because fibrosis progression determines long-term liver-related risk. Screening high-risk metabolic patients creates an identifiable population for non-invasive testing and specialist evaluation. In the European LiverScreen study, 70% of screened participants had at least one metabolic risk factor, reinforcing the strong relationship between metabolic health and undiagnosed liver disease. Treatment manufacturers are responding with therapies designed to address both hepatic and systemic disease features.

Market Restraints

Complex patient identification and fibrosis staging continue to restrict treatment initiation.

MASH can remain asymptomatic for years, and routine liver enzymes do not reliably identify the patients with clinically important fibrosis. This produces a substantial diagnostic gap between underlying disease prevalence and the population formally diagnosed with treatment-relevant steatohepatitis. Biopsy remains informative but is poorly suited to population-scale screening because it is invasive and requires specialist resources.

Non-invasive methods are improving this pathway, but they can produce discordant findings that require clinical interpretation. Fibrosis scores, elastography, imaging, metabolic risk factors, and laboratory markers must often be considered together before treatment is selected. In the multinational European LiverScreen cohort, confirmed chronic liver disease with fibrosis was identified in 1.6% of the screened population, illustrating how broad metabolic risk must be narrowed into clinically actionable disease. Diagnostic uncertainty can delay prescription, restrict payer approval, and reduce the number of patients entering specialist treatment pathways.

Market Opportunities

Combination therapy creates opportunities to treat hepatic fibrosis and systemic metabolic dysfunction simultaneously.

MASH is biologically heterogeneous, which limits the likelihood that one pharmacological mechanism will be optimal for every patient phenotype. Some patients have dominant obesity and insulin resistance, while others exhibit aggressive fibrogenesis or liver-centered disease despite different metabolic profiles. This creates opportunities for combinations integrating liver-directed, metabolic, anti-inflammatory, and genetic mechanisms.

Drug developers are increasingly designing programs around complementary biological effects rather than competing exclusively through monotherapy. Resmetirom combinations with GLP-1 receptor modulation, DGAT-2 inhibition, and RNA-based genetic targets illustrate this strategy. FGF21 analogues and pan-PPAR agonists create additional combination possibilities if late-stage studies establish favorable benefit-risk profiles. A market assessment placed the drug-treatment segment at 78.58% share of the broader MASH treatment field, showing the central role pharmacological innovation already plays in the sector.

Market Challenges

Long-term confirmation of clinical benefit remains essential for sustained adoption.

Accelerated approvals can establish earlier treatment access, but manufacturers must continue generating evidence showing that improvements in liver histology translate into durable clinical outcomes. MASH progresses slowly, so demonstrating reductions in decompensation, cirrhosis progression, transplantation, cardiovascular events, or mortality requires extended follow-up. This creates long and operationally demanding development programs.

The challenge is intensified by changing standards of care. A candidate designed before approved therapies entered the market may eventually need to demonstrate efficacy against a stronger clinical benchmark or within a combination regimen. Companies must also recruit patients with accurately staged disease while controlling for weight changes, diabetes therapies, lifestyle intervention, and other metabolic treatments. Inventiva's NATiV3 program enrolled 1,009 patients in its main cohort, illustrating the scale required for modern late-stage MASH development.

Non-Alcoholic Steatohepatitis Treatment SWOT Analysis

Strengths

• The market now has validated disease-modifying pharmacological mechanisms, reducing the historical dependence on lifestyle management alone.

• MASH treatment can draw patients from hepatology, endocrinology, obesity medicine, gastroenterology, and primary-care pathways.

• Oral liver-directed therapy provides a practical chronic-treatment format suitable for long-term management.

• Non-invasive fibrosis assessment is improving patient identification and reducing dependence on routine biopsy.

• The therapeutic pipeline includes metabolic, anti-fibrotic, hormonal, genetic, and inflammation-focused mechanisms.

• Disease awareness is rising because MASH is increasingly recognized as a systemic cardiometabolic condition with serious liver complications.

• The approved resmetirom indication directly targets patients with F2–F3 fibrosis, establishing a clearly defined treatment population.

Weaknesses

• Large numbers of patients remain undiagnosed because early-stage disease commonly lacks specific symptoms.

• Fibrosis staging can vary between non-invasive methods, creating uncertainty in treatment eligibility.

• Specialist capacity differs considerably between countries and healthcare systems.

• Long-term therapy requires adherence, repeated monitoring, and continued management of metabolic comorbidities.

• Some historic drug candidates failed late-stage development, demonstrating the difficulty of translating liver-fat changes into accepted clinical endpoints.

• Terminology has shifted from NASH to MASH, creating temporary inconsistency in patient education, medical coding, research databases, and market communication.

• In one large European screening program, 4.6% of participants recorded elevated liver stiffness, emphasizing the screening burden required to identify appropriate patients.

Opportunities

• Screening programs for people with diabetes and obesity can identify treatment candidates earlier in fibrosis progression.

• Combination regimens can address metabolic dysfunction and hepatic fibrosis through complementary mechanisms.

• Oral incretin candidates could widen access for patients who prefer tablets over injectable treatment.

• Genetic therapies targeting PNPLA3 and other validated disease pathways create opportunities for precision treatment.

• FGF21 analogues offer a differentiated route for patients with advanced metabolic and fibrotic disease.

• Emerging markets can expand as specialist liver services, elastography capacity, and chronic-disease treatment access improve.

• Asia-Pacific represented 22.44% of the global NASH/MASH treatment market in a 2025 assessment, highlighting substantial headroom outside established Western markets.

Threats

• Strong competition from established obesity and diabetes medicines can shift physician attention toward multipurpose metabolic therapies.

• Late-stage clinical failure can remove years of development investment from a company's pipeline.

• Restrictive reimbursement criteria can limit treatment to narrowly defined fibrosis populations.

• Safety concerns can reduce adoption when therapies require additional liver, lipid, gallbladder, gastrointestinal, or metabolic monitoring.

• New entrants may pressure first-generation therapies through greater convenience, broader indications, or stronger multi-organ effects.

• Treatment standards may evolve rapidly as combination data mature.

• The top ten competitors collectively held only 9.15% market share in a 2024 competitive assessment, showing a fragmented structure in which future entrants can materially alter competitive positioning.

Non-Alcoholic Steatohepatitis Treatment Segmentation Analysis

The Non-Alcoholic Steatohepatitis Treatment Market can be segmented by drug, disease stage, and distribution channel. These categories reflect how therapy selection changes according to mechanism, fibrosis severity, prescription setting, and ongoing patient management requirements. Drug segmentation is evolving most rapidly because approved therapies now coexist with established off-label approaches and late-stage candidates. Disease-stage segmentation is clinically important because current disease-specific treatment is concentrated in noncirrhotic patients with meaningful fibrosis rather than the entire MASLD population. Distribution channels differ according to payer authorization, specialist prescribing, chronic refill requirements, and pharmacy support services. Hospital and specialty channels remain important for treatment initiation, while retail-access models can become increasingly relevant as prescribing pathways mature.

By Drug

Vitamin E and pioglitazone historically played an important off-label role because clinicians lacked approved disease-specific medicines. Resmetirom changed this structure by introducing an oral THR-β agonist designed specifically for fibrotic noncirrhotic MASH. Semaglutide adds an incretin-based option with established effects on weight and metabolic risk factors. Lanifibranor remains an important late-stage oral pan-PPAR candidate, while additional programs involving obeticholic acid, aramchol, cenicriviroc, and other mechanisms have contributed to the development history of the sector.

Current drug competition increasingly centers on fibrosis improvement, steatohepatitis resolution, cardiometabolic benefit, route of administration, and long-term tolerability. A 2025 therapeutic-drug dataset assigned 60.15% share to THR-β agonists, supporting the strong early commercial position created by resmetirom. Future drug mix will depend on new approvals and whether investigational therapies can demonstrate differentiated efficacy in advanced fibrosis or cirrhotic populations.

By Disease Stage

NASH Stage F0 includes inflammatory disease without established fibrosis, while F1 represents early fibrosis. F2 marks clinically significant fibrosis and has become particularly important because approved pharmacotherapy targets patients with meaningful but noncirrhotic liver scarring. F3 represents advanced bridging fibrosis and carries greater risk of progression to cirrhosis. F4 represents cirrhosis, a population with higher clinical complexity and a different treatment-risk profile.

The commercial center of the Non-Alcoholic Steatohepatitis Treatment Market is increasingly concentrated on F2 and F3 patients because this group combines substantial progression risk with an established regulatory treatment pathway. Earlier-stage patients remain important for monitoring, lifestyle intervention, metabolic control, and future preventive pharmacotherapy. F4 disease represents a major research opportunity because preventing decompensation and improving cirrhotic fibrosis would address significant unmet need. A market assessment identified significant and advanced fibrosis as the leading disease-stage category with 34.83% share.

By Distribution Channel

Hospital pharmacies support complex MASH treatment because therapy initiation often follows specialist assessment, fibrosis testing, multidisciplinary review, or hospital-based hepatology care. These pharmacies can coordinate high-cost specialty medicines, medication reconciliation, safety monitoring, and institutional treatment protocols. Retail and specialty pharmacies play a growing role once a patient has a stable prescription and requires recurring access, adherence support, insurance coordination, and home delivery. Other pharmacies include smaller channels and evolving digital dispensing models.

Specialty-pharmacy capabilities are particularly relevant to MASH because treatment authorization may require documentation of fibrosis stage, prior testing, metabolic comorbidities, and prescriber qualifications. As disease-specific therapy becomes normalized, dispensing could progressively shift toward outpatient channels without eliminating hospital involvement in diagnosis and treatment initiation. A 2025 treatment dataset assigned 44.84% share to hospital pharmacies, making them the largest distribution channel in that assessment.

Regional Analysis

Regional performance in the Non-Alcoholic Steatohepatitis Treatment Market reflects differences in obesity prevalence, diabetes burden, specialist availability, regulatory approvals, reimbursement systems, fibrosis-screening infrastructure, and awareness of metabolic liver disease. North America remains the most mature pharmacotherapy market, while Europe is expanding access following regulatory milestones. Asia-Pacific has a large metabolic-risk population and strengthening hepatology infrastructure. Middle East & Africa presents long-term opportunities but remains affected by uneven diagnosis and access. A 2025 regional assessment placed the combined market outside North America, Europe, and Asia-Pacific at 4.92%, illustrating the commercial concentration that still exists in established treatment markets.

• North America: North America has the most developed Non-Alcoholic Steatohepatitis Treatment Market because U.S. regulators were first to authorize disease-specific pharmacotherapy. The region benefits from established hepatology practices, specialty pharmacies, obesity clinics, diabetes centers, advanced imaging, elastography, pathology capacity, and clinical-trial networks. U.S. treatment pathways increasingly integrate non-invasive fibrosis scores with specialist evaluation to identify patients most likely to benefit from pharmacological intervention.

  Commercial adoption is also supported by broad physician familiarity with incretin therapies. Semaglutide was already widely used in obesity and diabetes care before receiving a MASH indication, giving clinicians experience with its administration and safety profile. Resmetirom created a distinct liver-directed pathway that can be used in suitable fibrotic disease. Canada contributes through specialist liver centers and structured chronic-disease management, while U.S. prescription volume remains the primary regional driver. North America represented 50.85% market share in a 2025 therapeutic-drug assessment.

  Future regional competition will increasingly depend on earlier diagnosis. Large numbers of adults with obesity or diabetes can enter fibrosis-risk assessment through primary care and endocrinology rather than waiting for advanced liver symptoms. This favors manufacturers that provide straightforward prescribing criteria, payer-support systems, physician education, and evidence compatible with non-invasive diagnosis. Combination regimens and therapies targeting cirrhotic MASH could expand the eligible patient base further.

• Europe: Europe combines a substantial underlying metabolic disease burden with strong academic hepatology expertise and increasingly structured fibrosis-screening programs. Germany, France, the United Kingdom, Italy, Spain, and Nordic countries maintain active specialist networks and contribute extensively to multinational MASH clinical trials. Access, however, varies because national reimbursement processes can differ even after centralized regulatory authorization.

  The European market is also strongly influenced by health-system emphasis on identifying high-risk patients rather than conducting unrestricted population treatment. Diabetes, obesity, elevated liver enzymes, abnormal fibrosis scores, and elastography findings can direct referrals toward hepatology. This approach supports efficient allocation of disease-specific medicines while strengthening demand for validated non-invasive tools.

  Europe held 24.33% market share in a 2025 therapeutic-drug assessment. The region's future position will depend on reimbursement timing, prescribing guidelines, specialist capacity, and competition between liver-specific and metabolic agents. Resmetirom's European authorization established a direct pharmacological pathway, while semaglutide and other metabolic treatments broaden the competitive framework. European developers also remain active in pipeline development, with Inventiva's lanifibranor program representing one of the most advanced oral candidates.

• Asia-Pacific: Asia-Pacific represents a major long-term Non-Alcoholic Steatohepatitis Treatment Market because large populations in China, India, Japan, South Korea, and Southeast Asia face increasing burdens of diabetes, obesity, central adiposity, and metabolic syndrome. Asian patients can develop metabolic liver disease at lower body-mass-index thresholds than many Western populations, making risk-based screening particularly relevant.

  Japan has a mature pharmaceutical system and specialist hepatology infrastructure, while China continues expanding chronic metabolic-disease management and advanced diagnostics. India combines a large diabetes population with rapid growth in private healthcare, diagnostic imaging, and specialty medicine. South Korea and Australia contribute through established clinical research and advanced liver-care centers.

  Asia-Pacific represented 19.9% market share in a 2025 therapeutic-drug assessment. Expansion will depend on affordability, local regulatory approvals, physician education, and the availability of non-invasive fibrosis testing. Manufacturers that can integrate MASH treatment with diabetes and obesity care may gain a strategic advantage because the same healthcare networks already manage many high-risk patients. Local clinical evidence will also become increasingly important as regulators and physicians evaluate treatment effects across different metabolic phenotypes.

• Middle East & Africa: The Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market is shaped by contrasting healthcare environments. Gulf countries have advanced hospitals, high specialist density in major cities, and significant burdens of obesity and diabetes, creating favorable conditions for premium liver therapies. African markets show wider variation in diagnostic capacity, specialist access, insurance coverage, and availability of non-invasive fibrosis testing.

  Saudi Arabia and the UAE are important potential treatment centers because metabolic disease management has become a major public-health priority. South Africa provides another focal point through specialist gastroenterology and hepatology infrastructure. Wider adoption across the region requires stronger identification of patients before cirrhosis, expanded primary-care awareness, and greater availability of elastography and laboratory fibrosis pathways.

  A published industry assessment assigned the Middle East & Africa 5% of the global NASH market in 2024. The long-term opportunity lies in connecting diabetes and obesity clinics with liver screening. Pharmaceutical companies can also strengthen adoption through physician training, patient-support initiatives, local evidence generation, and partnerships with tertiary-care hospitals.

Competitive Landscape

The Non-Alcoholic Steatohepatitis Treatment Market is transitioning from a fragmented research field into a competitive specialty-pharmaceutical category. Madrigal Pharmaceuticals established first-mover advantage through resmetirom, creating a liver-directed commercial pathway and building physician familiarity with disease-specific treatment. Novo Nordisk entered the MASH treatment field through semaglutide, leveraging extensive experience in obesity, diabetes, and cardiometabolic care. Their strategies illustrate two different competitive models: dedicated hepatology specialization and broad metabolic-platform expansion.

Pipeline companies are competing through differentiated mechanisms. Inventiva is developing lanifibranor as an oral pan-PPAR agonist. Novo Nordisk strengthened its MASH portfolio through Akero Therapeutics and the FGF21 analogue efruxifermin. Boehringer Ingelheim is advancing survodutide, linking glucagon and GLP-1 receptor activity. Additional companies are pursuing genetic targets, lipid metabolism, inflammation, fibrosis biology, and multi-agonist approaches.

The competitive environment remains open because future treatment could require combinations rather than a single universal drug. One industry analysis assigned 6.93% market share to Madrigal Pharmaceuticals in 2024, making it the largest individual competitor in that dataset. Competitive strength will increasingly depend on clinical outcomes, fibrosis efficacy, metabolic benefits, ease of administration, payer access, safety, physician confidence, and ability to treat broader disease stages. Companies with assets capable of addressing cirrhotic MASH could gain additional differentiation because this population remains a major unmet-need segment.

List of Top Non-Alcoholic Steatohepatitis Treatment Companies

• Madrigal Pharmaceuticals, Inc. (U.S.)

• Novo Nordisk A/S (Denmark)

• Inventiva S.A. (France)

• Gilead Sciences, Inc. (U.S.)

• AbbVie Inc. (U.S.)

• Galmed Pharmaceuticals Ltd. (Israel)

• Galectin Therapeutics Inc. (U.S.)

• NGM Biopharmaceuticals, Inc. (U.S.)

• Bristol Myers Squibb (U.S.)

• Akero Therapeutics, Inc. (U.S.)

• Boehringer Ingelheim (Germany)

• Eli Lilly and Company (U.S.)

• Novartis AG (Switzerland)

Leading Companies by Market Share

• Madrigal Pharmaceuticals: Madrigal holds the strongest established position in disease-specific MASH pharmacotherapy through Rezdiffra, the first FDA-approved medicine specifically targeting adults with noncirrhotic MASH and moderate-to-advanced fibrosis. Its first-mover position has allowed the company to build dedicated hepatology prescribing relationships, treatment-support infrastructure, real-world evidence, and physician experience before several late-stage competitors reach the market. A competitive industry assessment assigned Madrigal 7% market share, the highest individual company share in that analysis.

• Novo Nordisk: Novo Nordisk occupies a distinct competitive position because semaglutide combines MASH treatment potential with established use across obesity and metabolic disease management. The company can leverage relationships with endocrinologists, obesity specialists, primary-care physicians, and cardiometabolic prescribers while expanding into liver care. Its acquisition strategy has also strengthened the company's pipeline beyond semaglutide by adding FGF21-based development expertise. A competitive assessment assigned Novo Nordisk 1.41% market share, placing it second among individually identified pharmaceutical competitors in that dataset.

Investment Trends & Opportunities

Investment in the Non-Alcoholic Steatohepatitis Treatment Market is increasingly directed toward clinically validated mechanisms, late-stage assets, and combination platforms. The sector previously carried high development risk because numerous compounds failed to produce sufficient improvements in fibrosis or steatohepatitis. Regulatory validation of resmetirom and semaglutide changed that investment thesis by demonstrating that pharmacological treatment can achieve accepted endpoints and enter clinical practice.

Capital allocation is now moving toward FGF21 analogues, incretin-based medicines, oral metabolic agents, pan-PPAR agonists, fibrosis-targeting compounds, and precision genetic approaches. Strategic buyers are particularly interested in programs that can complement existing obesity, diabetes, or liver portfolios. Novo Nordisk's acquisition of Akero Therapeutics was announced with potential consideration of up to US$5.2 billion, reflecting the strategic value assigned to efruxifermin and advanced MASH development capabilities.

Another investment opportunity lies in diagnostics. Wider pharmacological treatment requires scalable fibrosis identification, creating demand for elastography systems, blood-based biomarkers, digital risk algorithms, imaging technologies, and referral platforms. Investors are also focusing on real-world data infrastructure because long-term evidence will influence payer decisions and physician confidence.

Geographic expansion represents a further opportunity. Europe and Asia-Pacific contain large metabolic-risk populations but remain less commercially penetrated than the U.S. market. Companies with strong regulatory, reimbursement, and specialist-engagement capabilities can therefore build value by extending approved therapies internationally while preparing next-generation products for broader fibrosis stages.

Product Innovation & Development

Product development in the Non-Alcoholic Steatohepatitis Treatment Market is evolving toward multi-mechanism treatment. Resmetirom demonstrated that selectively activating thyroid hormone receptor beta can improve key liver-disease measures while maintaining oral administration. Semaglutide established an alternative approach based on GLP-1 receptor activity, linking hepatic improvement with systemic metabolic effects.

The next wave of innovation includes FGF21 analogues such as efruxifermin, pan-PPAR agonists such as lanifibranor, glucagon/GLP-1 dual agonists such as survodutide, oral GLP-1 compounds, DGAT-2 inhibitors, and RNA-based therapies. These programs seek to address fibrosis, hepatic fat, inflammation, insulin resistance, weight, and genetic susceptibility through different biological pathways.

Precision medicine is becoming especially important. PNPLA3 is a genetically validated risk factor for steatotic liver disease, creating opportunities for RNA interference technologies designed to suppress disease-driving pathways. Combination programs may pair these precision therapies with established liver-directed drugs.

Madrigal initiated Phase 1 dosing of its oral GLP-1 candidate MGL-2086 in June 2026, supporting development of a potential oral combination with resmetirom. This strategy demonstrates how product innovation is moving beyond standalone therapies toward regimens designed to treat both hepatic pathology and metabolic dysfunction. Future differentiation will depend on fibrosis outcomes, long-term safety, dosing convenience, treatment persistence, and compatibility with existing obesity and diabetes medicines.

Recent Developments (2023–2026)

• In March 2024, Madrigal Pharmaceuticals received FDA accelerated approval for Rezdiffra to treat adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis, establishing the first disease-specific pharmacological treatment in the United States.

• In August 2025, Novo Nordisk received FDA approval for Wegovy in adults with noncirrhotic MASH and moderate-to-advanced fibrosis, adding a GLP-1-based treatment option to the therapeutic landscape.

• In October 2025, Novo Nordisk agreed to acquire Akero Therapeutics, adding the FGF21 analogue efruxifermin and strengthening its late-stage MASH development portfolio.

• In February 2026, Madrigal Pharmaceuticals expanded its MASH pipeline through licensing arrangements covering preclinical siRNA programs intended to complement its established resmetirom platform.

• In July 2026, Madrigal Pharmaceuticals reported that its oral GLP-1 development program had entered Phase 1 testing as part of a strategy to create combination treatments anchored by Rezdiffra.

• In September 2026, Inventiva announced completion of the final patient visit in the NATiV3 Phase 3 study of lanifibranor, advancing the oral pan-PPAR candidate toward its planned late-stage efficacy readout.

Scope of the Non-Alcoholic Steatohepatitis Treatment Market Report

The Non-Alcoholic Steatohepatitis Treatment Market report evaluates the evolving therapeutic landscape for patients with metabolic dysfunction-associated steatohepatitis across drug classes, fibrosis stages, distribution channels, regions, and competitive strategies. The coverage includes established off-label therapies, approved disease-specific medicines, late-stage clinical candidates, combination programs, and emerging mechanisms designed to address liver fibrosis and systemic metabolic dysfunction.

The report assesses drug segmentation across vitamin E and pioglitazone, obeticholic acid, lanifibranor, semaglutide, resmetirom, aramchol, cenicriviroc, and other therapies. Disease-stage analysis covers F0, F1, F2, F3, and F4 populations, with particular attention to how fibrosis severity affects treatment eligibility, specialist referral, monitoring, and clinical development.

Distribution coverage examines hospital pharmacies, retail and specialty pharmacies, and other pharmacy channels. Regional analysis addresses North America, Europe, Asia-Pacific, and Middle East & Africa while considering regulatory access, diagnostic capacity, metabolic disease burden, clinical infrastructure, and adoption of non-invasive fibrosis testing.

Competitive coverage includes commercial positioning, pipeline depth, product differentiation, partnerships, acquisitions, regulatory milestones, and new treatment mechanisms. The report also tracks clinical innovation across THR-β agonists, GLP-1 receptor therapies, FGF21 analogues, PPAR agonists, genetic medicines, and combination regimens.

The scope incorporates developments through September 2026, enabling assessment of the current transition from a historically underserved liver disease category into an active specialty-treatment market characterized by approved pharmacotherapy, late-stage innovation, expanding diagnostic pathways, and increasing competition among hepatology and cardiometabolic drug developers.